de la Torre R, et al. - In 27 adults (18-55 years) with Fragile-X syndrome (FXS), researchers tested the safety and effectiveness of epigallocatechin-3-gallate (EGCG) and cognitive training. For this investigation, EGCG (5-7 mg/kg/day) combined with cognitive training (CT) was given to participants with FXS for 3 months, with 3 months of follow-up after discontinuation of treatment. Investigators found that, compared to subjects receiving Placebo+CT, FXS patients receiving EGCG+CT significantly improved cognition (visual episodic memory) and functional skills (ABAS II-Home Living skills) in daily life. Overall, they suggested that phase 2 clinical trials are needed in larger groups of subjects to determine EGCG's therapeutic potential for improving cognition and daily life skills in FXS.